These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2851746)

  • 1. [Use of calcium channel blockers in neurology].
    Ryglewicz D; Członkowska A
    Neurol Neurochir Pol; 1988; 22(3):240-5. PubMed ID: 2851746
    [No Abstract]   [Full Text] [Related]  

  • 2. [New therapeutic concepts in cerebrovascular insufficiency].
    Wender M
    Neurol Neurochir Pol; 1986; 20(5):401-3. PubMed ID: 3587509
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey.
    Nakajima M; Adachi I; Ueda M
    Arzneimittelforschung; 1993 Dec; 43(12):1276-82. PubMed ID: 8141814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ion channels of vascular smooth muscle and pharmacological effects of calcium antagonists and potassium channel openers].
    Kitamura K; Ogata R
    Fukuoka Igaku Zasshi; 1994 Nov; 85(11):309-13. PubMed ID: 7851831
    [No Abstract]   [Full Text] [Related]  

  • 5. Vascular effects of calcium antagonists. Uses in some cerebrovascular disorders.
    Marin J
    Gen Pharmacol; 1988; 19(3):295-306. PubMed ID: 2458295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advance in calcium channel blockers relaxing corpus cavernosum smooth muscle].
    Xiao HJ; Liu JH
    Zhonghua Nan Ke Xue; 2003 Feb; 9(1):55-7. PubMed ID: 12680335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates Ca2+ influx in brain vascular smooth muscle cells.
    Matsuoka T; Nishizaki T; Nomura T
    Biochem Biophys Res Commun; 1997 Nov; 240(2):484-7. PubMed ID: 9388505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells.
    Wu BN; Chen ML; Dai ZK; Lin YL; Yeh JL; Wu JR; Chen IJ
    Vascul Pharmacol; 2009; 51(2-3):65-71. PubMed ID: 19298869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of Ca2+ in the pathogenesis of epilepsy. Calcium antagonists--a new class of anticonvulsants].
    Glebov RN; Karpova MN
    Patol Fiziol Eksp Ter; 1990; (3):57-61. PubMed ID: 2169039
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of anisodamine and dauricine on proliferation, DNA synthesis, and calcium influx in bovine anterior cerebral arterial smooth muscle cells in culture.
    Zeng GQ; Rui YC
    Zhongguo Yao Li Xue Bao; 1991 Jul; 12(4):308-11. PubMed ID: 1807078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structurally novel antihypertensive compound, McN-5691, is a calcium channel blocker in vascular smooth muscle.
    Flaim SF; Gleason MM; Hedberg A; Shank RP; McCullough JR; Gill A; Damiano BP; Brannan MD; Carson JR
    J Pharmacol Exp Ther; 1991 Jan; 256(1):279-88. PubMed ID: 1846419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From channels to cats: an overview of isradipine pharmacology.
    Rüegg UT; Hof RP
    Cor Vasa; 1990; 32(2 Suppl 1):12-22. PubMed ID: 2166635
    [No Abstract]   [Full Text] [Related]  

  • 13. [New findings on calcium antagonism].
    Ferrari R; Ceconi C; Curello S; Visioli O
    Ann Ital Med Int; 1992; 7(3 Suppl):100S-111S. PubMed ID: 1338419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium antagonistic vasodilator mechanisms of brovincamine fumarate studied in canine cerebral artery.
    Tanaka Y; Morimoto K; Ishii K; Nakayama K
    Arzneimittelforschung; 1994 Jul; 44(7):803-8. PubMed ID: 7945512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance.
    Triggle DJ
    Cleve Clin J Med; 1992; 59(6):617-27. PubMed ID: 1330367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic deficit in nitric oxide elicits oxidative stress and augments T-type calcium-channel contribution to vascular tone of rodent arteries and arterioles.
    Howitt L; Kuo IY; Ellis A; Chaston DJ; Shin HS; Hansen PB; Hill CE
    Cardiovasc Res; 2013 Jun; 98(3):449-57. PubMed ID: 23436820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action of calcium antagonists in the treatment of vascular diseases].
    Mayerhofer S
    Wien Med Wochenschr; 1986 Nov; 136(21-22):591-4. PubMed ID: 2435066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nervous disease & Ca antagonist].
    Otomo E
    No To Shinkei; 1990 Jan; 42(1):33-41. PubMed ID: 2337488
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers.
    Schachter M
    Int J Cardiol; 1997 Dec; 62 Suppl 2():S85-90. PubMed ID: 9488199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antihypertensive therapy and vascular wall protection with special reference to calcium antagonists].
    Faulhaber HD
    Z Arztl Fortbild (Jena); 1993; 87(9 Suppl 5):1-5. PubMed ID: 8237075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.